PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV

Wegovy, Zepbound, Foundayo Comparison | Which Medicare Bridge Program Medication Is Right for You?

12:01Jul 2026

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

The speaker, who runs the channel Beyond the Scale and says she documents her own Zepbound journey, compares the three medications covered by the Medicare GLP-1 bridge program: Wegovy, Zepbound and Foundayo. She states up front that she is not a doctor and that nothing in the video is medical advice. According to the video, the program currently runs through December 2027, charges a flat $50 monthly co-pay, and generally requires Medicare Part D, prior authorization to meet BMI requirements, and medical eligibility such as obesity or overweight with a qualifying risk factor.

Published by Beyond the Scale: My GLP-1 Journey on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

She describes Wegovy as the longest-established option, with extensive research, proven cardiovascular benefits for certain eligible patients, and both injectable and oral forms in the program. She says studies comparing semaglutide with tirzepatide found greater average weight loss with tirzepatide. Zepbound acts on both the GIP and GLP-1 receptors, and she says it produced the greatest average weight loss of the three in clinical studies. The bridge program currently covers only the QuickPen version. Foundayo is a daily tablet with no needles, but she notes it is newer and has less long-term real-world experience.

The speaker says the common side effects are similar across all three, including nausea, vomiting, diarrhea, constipation, stomach pain, indigestion and reduced appetite, and that they often ease as the body adjusts and doses rise gradually. She says the bridge program covers weight management, so people treated for type 2 diabetes may instead be covered under regular Part D, with costs depending on their plan. She frames the choice as a conversation to have with a health care provider, not a search for a single best drug.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 1:06 The speaker says the bridge program runs through December 2027 with a flat $50 monthly co-pay and generally requires Part D, prior authorization and meeting BMI and medical criteria.
  2. 2:07 She explains that Zepbound works on both GIP and GLP-1 receptors, while Wegovy and Foundayo primarily act on the GLP-1 receptor.
  3. 2:39 She describes Wegovy as the longest track record, with cardiovascular benefits for certain patients and both injection and oral forms in the program.
  4. 4:13 She says Zepbound showed the greatest average weight loss in studies, but the program covers only the QuickPen version.
  5. 4:46 She describes Foundayo as a daily tablet with no needles, though it has less long-term real-world experience.
  6. 8:26 She says people treated for type 2 diabetes may be covered under regular Part D instead of the bridge program, with costs depending on their plan.

Key moments

Tap one to play from there.

  1. 0:00 Introduction and who qualifies for the Medicare Bridge Progr
  2. 2:11 Let's Meet the Three Covered GLP-1 Medications in the Medica
  3. 5:53 Which GLP-1 Medication Might Fit Different People?
  4. 6:39 Side Effects: What Do They Have in Common?
  5. 8:43 What If You Are On Medicare and Have Type 2 Diabetes?
  6. 9:15 So...Which GLP-1 Medication Is Right for You?

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy, Zepbound, Foundayo and semaglutide

Questions this video answers

How much does the Medicare GLP-1 bridge program cost per month?

According to the video, eligible beneficiaries pay a flat $50 monthly co-pay. The speaker says the program currently runs through December 2027 and generally requires Part D coverage, prior authorization and meeting BMI and medical eligibility criteria.

Which medications are covered by the Medicare GLP-1 bridge program?

The speaker names three: Wegovy, Zepbound and Foundayo. She says Wegovy is available in injectable and oral forms, Zepbound is covered only as the QuickPen, and Foundayo is a daily tablet.

Do Wegovy, Zepbound and Foundayo have different side effects?

She says they have a lot in common because all work through the GLP-1 pathway. She lists nausea, vomiting, diarrhea, constipation, stomach pain, indigestion and reduced appetite, and says these often improve as the body adjusts to gradual dose increases.

Does the Medicare bridge program cover diabetes medications?

The speaker says the bridge program covers medications for weight management. She says that if a provider is treating type 2 diabetes, drugs such as Ozempic or Mounjaro may instead be covered under regular Part D, with coverage and costs depending on the individual plan.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Does Medicare cover GLP-1s? Ozempic, Wegovy and Zepbound, route by route

    Yes, by two different routes. Medicare drug plans (Part D, including Medicare Advantage plans with drug coverage) cover Ozempic and Mounjaro for type 2 diabetes. For weight loss, the Medicare GLP-1 Bridge covers Wegovy (pen or pill), the Zepbound KwikPen and Foundayo for a $50 monthly copay from 1 July 2026 to 31 December 2027, if you meet CMS's BMI criteria. The catch: the Bridge runs outside Part D, so that $50 never counts toward your deductible or out-of-pocket cap.

  • Who qualifies for Wegovy and Zepbound? The BMI rules, the conditions, and what your plan adds

    You qualify for Wegovy or Zepbound for weight loss as an adult with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or high cholesterol. Wegovy also treats adults with heart disease at BMI 27 and up, and a liver disease called MASH; Zepbound also treats sleep apnea at BMI 30 and up. Insurers often ask for more: Aetna's 2026 policy wants BMI 35 and six months in a weight program, and Medicare's Bridge wants BMI 35, or 30 or 27 with specific conditions.

  • Zepbound vs Wegovy: the two weight-loss brands, priced every way you can buy them

    Zepbound is tirzepatide and Wegovy is semaglutide, and in the one trial that ran them head-to-head, tirzepatide's molecule lost 20.2% of body weight against 13.7% over 72 weeks. That settles which is stronger. What it does not settle is which you can afford: Zepbound self-pay runs $299 to $699 a month by dose, Wegovy's pen is $349 flat and its new tablet starts at $149, and with a commercial plan that covers either, both fall to $25.

Next steps

Wegovy prices

Insurance

Find more like it

Side effectsDose changeInjection techniqueCost and insuranceHow it worksThe trials

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV